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1. Introduction 
In the primary care setting blood samples are frequently taken, following clinical 
assessment, in order to determine a patient’s iron status. This chapter will describe the 
laboratory tests used to assess iron status and explain interpretation of results with respect 
to both iron deficiency and iron overload.  
Reduced serum ferritin values confirm iron deficiency and are hugely helpful in the 
investigation of patients with anaemia. It has however, also been shown that elevated serum 
ferritin is a common finding in the primary care population (Ogilvie et al, 2010) and that 
General Practioners (GPs) may require more guidance from Haematologists in the 
management of patients with raised serum ferritin levels. This will be explained and 
discussed with the aim of ultimately improving the diagnosis of serious underlying 
conditions including Hereditary Haemochromatosis (HHC). 
2. Laboratory tests 
Laboratory tests assessing body iron status are performed in both the Haematology and 
Biochemistry departments. Serum ferritin and iron studies are most commonly requested.  
2.1 Serum ferritin 
In simple terms ferritin can be described as the intracellular protein which safely stores 
excess iron. Tiny amounts of ferritin can be detected in serum and this serum ferritin is the 
most frequently measured surrogate for body iron stores. The normal range for serum 
ferritin is generally regarded as 15-300μg/l. There is no known physiological role for serum 
ferritin but the results of quantitative phlebotomy studies have shown that 1μg/l of ferritin 
in serum is approximately equivalent to 8mg of stored reticuloendothelial system body iron. 
(Worwood, 1982).  
Serum ferritin shows an acute phase response and can be elevated in a variety of 
inflammatory, metabolic, hepatic and neoplastic disorders. This can make it difficult to 
recognise iron deficiency in patients with inflammatory disorders as such disorders can 
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cause serum ferritin to be elevated to levels inappropriate to the reticuloendothelial iron 
store.  
There are however also well recognised conditions that lead to gross inappropriate elevation 
of serum ferritin; hepatitis, juvenile Stills disease and disseminated malignancy.  
We know that total body iron content is 4g, with a daily requirement of only 1-2mg of iron. 
Body iron content is regulated by complex controls over iron absorption in the upper small 
bowel. The average Western diet provides 15-20mg of iron each day which is far in excess of 
the body requirement of 1-2mg iron per day. There are no regulatory pathways to eliminate 
iron from the body and losses occur only through shedding of cells in the GI tract, skin 
desquamation, pregnancy and menstrual loss. 
Around 3g of total body iron is present in mature or developing red blood cells. In the 
developing red cells, the erythroblasts, iron (Fe3+) is converted to iron (Fe2+) and is then 
combined with protoporphyrin to form haem. Haem is then combined with 2 alpha globin 
and 2 beta globin chains to form haemoglobin.  
The reticuloendothelial system is the main storage site of iron with approximately 0.5g of 
iron being found in macrophages. The reticuloendothelial system acquires its storage iron 
from the ingestion of effete red blood cells (lifespan 120 days) whereas other tissues accept 
iron from transferrin via transferrin receptors on the cell surface. Iron is found in all tissues 
but particularly as myoglobin in muscle, in hepatocytes and in many essential enzymes. Iron 
based enzymes can contain haem e.g. cytochrome P450 family, myeloperoxidase, 
lactoperoxidase and catalase or be non-haem iron based e.g. NADH dehydrogenase and the 
lipoxygenases.  
2.2 Iron sudies 
Iron studies in most laboratories include serum iron levels, serum transferrin or total iron 
binding capacity (TIBC), and transferrin saturation. Total iron binding capacity is a 
measurement of the maximum amount of iron that can be carried. It is therefore an indirect 
measurement of transferrin. 
The most useful test in assessing iron supply to the tissues is transferrin saturation. 
Transferrin is a glycoprotein synthesised in the liver and is responsible for the 
transportation of iron (Fe3+) in serum. This glycoprotein has 2 iron binding domains and is 
normally 30% saturated with iron. In iron deficiency, reduced transferrin saturation leads to 
iron deprivation for erythroblasts. In iron overload raised transferrin saturation leads to 
parenchymal iron overload. 
In iron deficiency anaemia the serum iron level falls. As a result the liver is stimulated to 
synthesise more transferrin and the transferrin saturation falls (usually <15%). In Hereditary 
Haemochromatosis (HHC), a condition characterised by iron overload, iron levels rise, 
transferrin synthesis is reduced and transferrin saturation may reach 100%.  
Serum iron concentration is a measurement of circulating iron (Fe³+) bound to transferrin. 
Only 0.1% of total body iron is bound to transferrin at any one time. In addition, the 
transferrin iron pool turns over 10-20 times each day which is reflected in varying serum 
iron levels. Serum iron levels can fluctuate throughout the day so that measurement of 
serum iron concentration alone provides little useful clinical information.  
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Fig. 1. Normal Iron Homeostasis 
3. Iron deficiency 
The majority of laboratory requests for serum ferritin and iron studies are made following a 
clinical suspicion of possible iron deficiency. As iron deficiency develops transferrin 
saturation falls to <15% and serum ferritin levels are reduced. Thereafter full blood count 
(FBC) parameters become abnormal, with reduced haemoglobin, low mean corpuscular 
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haemoglobin (MCH) and low mean corpuscular volume (MCV) i.e. a hypochromic 
microcytic anaemia.  
In the developed world IDA is most commonly seen in young women as a result of 
menstruation and pregnancies (each pregnancy costs the mother 500mg of iron through iron 
transfer to foetus and blood loss at delivery). However IDA also occurs in 2-5% of males and 
post-menopausal females. Blood loss from the gastro-intestinal (GI) tract is the most 
common cause. The British Society of Gastroenterology recommends upper and lower GI 
investigations and to consider screening for coeliac disease. (Goddard et al, 2011) 
Specific issues are relevant in primary care. General Practioners often prescribe iron 
supplements and should be aware of the different elemental iron content of each 
preparation. For example, ferrous fumarate 210mg contains 68mg iron whereas ferrous 
gluconate 300mg contains 35mg iron. The amount of elemental iron often influences 
tolerability. Main side effects are gastrointestinal e.g. nausea and constipation. When such 
side effects lead to non compliance we suggest changing to a preparation containing less 
elemental iron. Patients who continue to have difficulty or cannot tolerate tablets may 
benefit from a syrup preparation. Syrups enable a smaller dose of elemental iron to be given. 
Parental infusions of iron should be reserved for those few patients who despite lower doses 
remain intolerant of oral iron. Iron infusion is also a treatment option for non compliant 
patients with significant anaemia. These patients should be referred and managed in 
secondary care. 
Recurrent IDA can be difficult to manage. In a male or post menopausal female patient with 
normal upper and lower GI endoscopies it can be difficult to determine when repeat 
investigations or further procedures e.g small bowel examination are needed. In these cases 
however reassurance must be taken from the endoscopic exclusion of GI malignancy as the 
cause of IDA. Clinical assessment, severity of anaemia, speed of recurrence and response to 
iron supplements can be helpful. Any patients causing ongoing concern should be referred 
to secondary care.  
4. Anaemia of Chronic Disease (ACD) 
Anaemia of chronic disease (ACD) is used to describe the anaemia that develops in response 
to chronic illness despite normal haematinic levels (normal B12, folate and ferritin) and 
without blood loss. Serum iron falls but unlike IDA the transferrin level also falls 
(Fitzsimons et al, 2002). There are 3 main causes of ACD; inflammatory, infectious or 
malignant disorders. ACD can cause either a normochromic normocytic anaemia or a 
hypochromic microcytic anaemia. The latter may be difficult to distinguish from iron 
deficiency anaemia as the serum ferritin level may be elevated by the acute phase response. 
However, in most cases of ACD the level of storage iron remains the most important factor 
controlling serum ferritin concentration. Serum ferritin levels >100μg/l are thought to 
indicate iron replete status and the presence of storage iron in inflammatory states – so 
excluding iron deficiency (Witte 1991). Measurement of other acute phase proteins e.g. C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR) and good clinical history and 
examination can help to distinguish ACD from IDA. Measurement of serum soluble 
transferring receptor (sTfR) can reliably distinguish IDA from ACD but this assay is seldom 
available from UK laboratories.  
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In ACD treatment of the underlying condition is the most important factor in correcting the 
anaemia. Many inflammatory conditions are managed in secondary or tertiary care and the 
use of monoclonal antibody therapy to inhibit cytokine response e.g. Infliximab in 
rheumatoid arthritis and inflammatory bowel disease has greatly influenced the course of 
such diseases and their associated chronic anaemias.  
General Practioners however may be required to manage chronic dysproteinaemic anaemia. 
This is often seen in patients with polymyalgia rheumatica (PMR) or temporal arteritis (TA). 
It can however be found without features of either PMR or TA. The anaemia is often 
hypochromic, microcytic and associated with elevated ESR >100mm/h, raised globulins 
without paraprotein. The anaemia is extremely sensitive to steroid although a small 
maintenance dose of prednisolone (ie 5mg daily) may be required longterm to maintain a 
normal haemoglobin. . (Fitzsimons and Brock, 2001) 
5. Summary of laboratory findings 
The table below summarises laboratory findings in the normal state, in iron deficiency 
anaemia, hereditary haemochromatosis and anaemia of chronic disease.  
 
 Normal Iron deficiency 
Anaemia 
Hereditary 
Haemochromatosis 
 
Anaemia of 
Chronic 
Disease 
Serum Ferritin 
 
ņ 
(15-300μg/l) 
Ņ ↑ ņ / ↑ 
Transferrin 
Saturation 
 
ņ 
(15-30%) 
Ņ ↑ Ņ 
Serum Iron 
 
ņ 
(10-30μg/l) 
Ņ ↑ Ņ 
Table 1. Summary of Laboratory Findings 
6. Hereditary Haemochromatosis 
Hereditary Haemochromatosis (HHC) is a particularly important diagnosis to be considered 
in the further investigation of patients with unexplained elevated serum ferritin level.  
6.1 Genetics of Hereditary Haemochromatosis 
Hereditary Haemochromatosis is inherited as an autosomal recessive disorder and is one of 
the most common single gene disorders in the North European population. In the United 
Kingdom (UK) it is estimated that approximately 250,000 people have the genetic 
predisposition yet only some 5000 people have been formerly diagnosed with HHC.  
The human haemochromatosis protein is named HFE – High iron (Fe). The mutation most 
commonly associated with HHC is the C282Y mutation. In the UK 8-12% of the population 
is heterozygous for C282Y (ie. carriers of HHC) and more than 90% of HHC cases are HFE 
homozygous for C282Y. Approximately 6% of cases are compound heterozygote for 
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C282Y/H63D. The cellular mechanisms by which HFE leads to increased iron gastro-
intestinal iron absorption and raised serum iron levels are not understood. 
6.2 Clinical features and treatment 
As transferrin saturation rises to >50% tissue iron uptake increases and can lead to end 
organ damage; hepatic cirrhosis (and hepatocellular carcinoma), cardiomyopathy, pituitary 
and thyroid gland impairment, diabetes mellitus, skin pigmentation (bronze diabetes), 
hypogonadism and arthropathy. The presenting features can therefore be varied and 
diagnosis delayed until iron stores are greatly increased (20-30g) and tissue damage has 
occurred. Disease is seldom evident at age <30yrs. Early diagnosis and damage prevention 
is essential. All morbidities, once the condition is recognised, can be either prevented or 
lessened with simple treatment – venesection.  
Phlebotomy is used to treat HHC with up to one unit of blood (500ml = 250mg iron) being 
venesected weekly. Serum ferritin and transferrin saturation are used to guide frequency of 
venesection (BCSH, 2002). The aim is to normalise iron stores - ferritin and transferrin 
saturation - and prevent end organ damage. Once this is achieved maintenance venesection 
should be tailored to maintain serum ferritin level <50μg/l and transferrin saturation <50%. 
It should be noted that in some patients transferrin saturations can remain >50% despite 
serum ferritin <50μg/l. We would suggest that these patients require more aggressive 
venesection programmes. 
6.3 Laboratory findings 
Biochemically HHC is characterised by an elevated (often grossly elevated) serum ferritin 
level, raised serum iron and increased transferrin saturation.  
Serum ferritin is highly sensitive to iron overload in HHC (BCSH guideline 2002). A high 
serum ferritin level however has low specificity for HHC as the majority of patients with 
raised ferritin levels do not have HHC. Careful clinical history taking and examination are 
therefore important. Subsequent appropriate investigations and interpretation of other acute 
phase proteins should enable prompt diagnosis of other conditions e.g. inflammatory or 
neoplastic conditions. It is important to note that, even when HHC has been excluded, a 
serum ferritin level >1000μg/l is often indicative of serious underlying pathology e.g 
disseminated malignancy, liver disease of any aetiology, inflammatory arthropathy. 
Serum ferritin is often elevated in hepatic cirrhosis of any aetiology. This is a major 
confounding factor in the use of serum ferritin in the diagnosis of HHC. The liver 
reticuloendothelial cells contain storage iron. The hepatocytes are a rich source of iron 
containing enzymes and ferritin. Any process which damages liver cells will release hepatic 
ferritin into the serum, causing an elevated level. It is also possible that liver impairment 
may interfere with the clearance of ferritin from the circulation and so further contribute to 
elevated levels. 
The combination of a raised serum ferritin level and increased transferrin saturation 
however is a powerful predictor for the clinical condition of HHC. A transferrin saturation 
>50% together with a raised serum ferritin level is predictive of homozygosity for the C282Y 
mutation of the HFE gene in 90% of males and 75% of females (Gordeuk et al 2008). 
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6.4 Genotype versus phenotype 
Assessment of body iron stores is of upmost importance in the diagnosis of HHC. Although 
the genetic predisposition to HHC is common, the disease penetrance is low i.e. not all 
people with the genetic predisposition for HHC go on to develop any evidence of iron 
overload or clinical disease.  
Approximately 1 in 300 people in the UK are homozygous for the C282Y mutation. 
However, only 38-50% of C282Y homozygotes will develop laboratory evidence of iron 
overload and 10-33% will develop any end organ damage (Whitlock et al 2006). The other 
factors influencing disease penetrance are not yet clearly established. Consequently, the UK 
National Screening Committee does not recommend molecular screening for HFE C282Y 
mutation in the asymptomatic population. 
We would recommend transferrin saturation as initial further investigation of elevated 
serum ferritin level. Clinical history and examination remain important as do other routine 
targeted laboratory investigations e.g liver enzymes. HFE genotyping is likely to be 
appropriate in patients with raised serum ferritin values when the transferrin saturation 
level ≥50%. 
6.5 Family screening 
Family screening is required for relatives of a patient with HHC. 
Such screening is important primarily to identify further homozygotes and to ensure 
prevention of iron overload and tissue damage. Secondly, screening allows reassurance of 
heterozygotes and those with a normal genotype. 
Laboratory screening tests should comprise assessment of iron stores (serum ferritin, serum 
iron and transferrin saturation) and HFE genotyping. Siblings and offspring of an affected 
family member should be screened. Given the high frequency of heterozygotes in the 
population (~10% in the UK), we would suggest that partners of known homozygous 
patients and heterozygous carriers should also be screened to identify the potential risk to 
any offspring. If both parents are heterozygous each child will have a 1 in 4 chance of being 
homozygous. If one parent is homozygous and the other heterozygous the risk of any child 
being homozygous is 1 in 2. 
Family members should be counselled as to the mode of inheritance of HHC, the 
importance of early diagnosis and the effectiveness and ease of treatment i.e iron overload 
and tissue damage can be prevented by simple venesection. 
The cartoon below (Figure 2) schematically demonstrates transferrin saturation; the 
transferrin protein (Y) combining with iron ( ). Two atoms of ferric iron bind to each 
transferrin molecule. 
7. Elevated serum ferritin levels in primary care 
Primary care physicians are often familiar with low serum ferritin values and the 
investigation and treatment of iron deficiency anaemia. However, a need for guidance in 
further investigation of elevated serum ferritin has recently been identified (Ogilvie et al, 
2010). 
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Fig. 2. The transferrin protein and iron binding. 
7.1 West of Scotland experience 
Greater Glasgow and Clyde (GG&C) is located on the West coast of Scotland and is the 
largest single Health Board in Scotland with a population of 1.4 million. During 2009 a total 
of 158,495 serum ferritin measurements were performed. Approximately 50% of samples 
were referred from primary care and 50% of these from patients >30 years of age. We 
surveyed all serum ferritin results obtained in our hospital from patients aged >30yrs in 
primary care during a 6 month period. All requests were initiated by the General Practioner 
and included 3029 females (73%) and 1141 males (27%).  
Only 8% of women aged 30-50 years had serum ferritin levels >100μg/l. In this age group 
IDA is the most frequent abnormalilty of iron metabolism reflecting the effects of 
menstruation and child birth. Mean serum ferritin levels rose progressively with female age. 
Serum ferritin levels >200μg/l were seen in 7.5% of women aged 50-59 years, 13% of women 
aged 60-69 years and 17% of women aged over 70 years. In contrast, irrespective of age, 17% 
of males over 30 years had serum ferritin levels >300μg/l. (Tables 2 and 3). 
A total of 59 patients had grossly elevated serum ferritin levels >1000μg/l (30 males, 29 
females). A review of the electronic individual patient case record was performed. In 27 
cases the grossly elevated serum ferritin level had been noted and an explanation given. 1 
patient was found to have Hereditary Haemochromatosis (HHC); 18 patients had non HHC 
liver disease (alcoholic liver disease, hepatitis C, hepatic steatosis). 10 of these 18 patients 
had HHC excluded (confirmed HFE genotype negative); 7 patients had disseminated 
malignancy. 1 patient had iron overload secondary to frequent packed red cell transfusion – 
required due to prosthetic cardiac valve haemolysis. 
www.intechopen.com
 
Serum Ferritin and Iron Studies – Laboratory Reporting and Clinical Application in Primary Care 
 
173 
However, more than half of patients (n=32) with grossly elevated serum ferritin levels were 
neither investigated nor referred to secondary care. The investigation of patients with serum 
ferritin values >1000μg/l is particularly important as it has been shown that the risk of 
cirrhosis in HHC occurs only with serum ferritin levels >1000μg/l. HHC is an easily 
treatable condition once identified. Iron depletion via venesection (500mls whole blood = 
250mg iron) can prevent end organ damage e.g. liver cirrhosis, diabetes. In addition, given 
the proportion of patients not further investigated, it is clear that more guidance to GPs on 
further management of these patients is needed. 
 
Male Patients 
Ferritin 
>100μg/l >200μg/l 300-1000μg/l >1000μg/l 
Age 
30-49yrs 
153 (58%) 80 (30%) 47 (18%) 11 (4%) 
50-69yrs 209 (53%) 118 (31%) 66 (17%) 9 (2%) 
70yrs + 245 (50%) 130 (26%) 84 (17%) 11 (2%) 
Table 2. Ferritin values in male patients >30yrs in Primary Care. 
 
Female 
Patients 
Ferritin 
>100μg/l >200μg/l 300-1000μg/l >1000μg/l 
Age 
30-49yrs 
101 (8%) 40 (3%) 15 (1.5%) 3 (0.3%) 
50-69yrs 
50-59yrs 
60-69yrs 
215 (28%) 
92 (22%) 
123 (35%) 
77 (10%) 
31 (7.5%) 
46 (13%) 
34 (4%) 
12 (3%) 
22 (6%) 
8 (1.0%) 
5 (1.0%) 
3 (1.0%) 
70yrs + 452 (38%) 206 (17%) 97 (8%) 16 (1.3%) 
Table 3. Ferritin values in female patients >30yrs in Primary Care 
7.2 Current reporting practice 
A survey of Scottish laboratories has shown that it is routine practice only to report serum 
ferritin levels >1000μg/l as ‘grossly elevated’. No further advice is currently provided. 
Given the above findings it would seem appropriate for laboratory reports to recommend 
hospital referral for all patients with serum ferritin level >1000μg/l, unless otherwise 
explained. It is as yet unclear as how best to advise General Practioners for patients with 
ferritin values between 300-1000μg/l. We would suggest further assessment of body iron 
stores with measurement of transferrin saturation. High transferrin saturation would then 
warrant further molecular screening for HHC. With the support of the Chief Scientist Office 
for Scotland we are now trying to establish an algorithm for the Scottish population based 
on age, sex, serum ferritin and transferrin saturation that might trigger a request for 
molecular screening for HHC. 
8. Conclusion 
We have discussed the use of laboratory tests to assess iron status in the primary care 
population. General Practioners frequently request serum ferritin levels and iron studies. 
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Often these tests are used to assess iron status when there is clinical suspicion of iron 
deficiency. General Practioners are familiar with the interpretation of these tests in iron 
deficiency (a reduced ferritin is irrefutable evidence of iron deficiency) but require more 
guidance when the serum ferritin level is elevated and iron overload is possible. Ferritin is 
an acute phase protein and can be elevated to levels inappropriately high for the degree of 
reticuloendothelial iron stores by infectious, neoplastic or inflammatory conditions. Even 
when HHC has been excluded a serum ferritin level >1000μg/l most often indicates 
significant underlying pathology and must be further investigated.  
HHC is an autosomal recessive disorder and is one of the most common single gene 
disorders in the North European population. The morbidities associated are serious and 
preventable. Timely diagnosis is therefore important and family screening of HHC patients 
is essential. Molecular screening of at risk but asymptomatic population (i.e Celts) is not 
recommended by the UK National Screening Committee as disease penetrance is <50%. 
Clear guidance is required to investigate patients with unexplained raised serum ferritin 
values. Elevation of serum ferritin level should prompt measurement of transferrin 
saturation and thereafter HFE genotype if saturation exceeds 50%. 
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